Outlook Therapeutics is remaining hopeful that the US Food and Drug Administration will approve its ONS-5010 bevacizumab candidate for wet age-related macular degeneration (AMD) despite the Phase III NORSE EIGHT study not meeting its primary endpoint of noninferiority, based on evidence that the drug still has biological activity.
Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss
Ophthalmic Bevacizumab Fails To Meet Primary Endpoint
The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.
More from Biosimilars
More from Generics Bulletin
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.
• By
Doubling down on previously shared data from the firm’s STELARIS trial, Teva has reported further findings from a survey featuring subjects and professionals involved in the Phase III study for its proposed long-acting olanzapine injectable.